-transparent.png){kind=logo}
In a randomized design study in 66 hypercholesterolemic patients, dosages of 10 g of colestipol HCl twice daily lowered serum cholesterol an average of 19% more than placebo therapy. These results are comparable to those in other studies in which the same total daily dose was given in three or four doses. The most common side effect was constipation, reported by 6 patients on colestipol HCl and 3 patients on placebo. No untoward systemic reactions or abnormal laboratory data were seen except for a slight rise in serum alkaline phosphatase during colestipol HCl therapy. The drug was well accepted by most patients.
Related Publications
K Gundersen, and
E E Cooper, and
G Ruoff, and
T Nikolai, and
J R Assenzo
January 1978,
Journal of chronic diseases,
K Gundersen, and
E E Cooper, and
G Ruoff, and
T Nikolai, and
J R Assenzo
December 1973,
Journal of the American Geriatrics Society,
K Gundersen, and
E E Cooper, and
G Ruoff, and
T Nikolai, and
J R Assenzo
December 1990,
The American journal of clinical nutrition,
K Gundersen, and
E E Cooper, and
G Ruoff, and
T Nikolai, and
J R Assenzo
January 1995,
Atherosclerosis,
K Gundersen, and
E E Cooper, and
G Ruoff, and
T Nikolai, and
J R Assenzo
January 2012,
Oxidative medicine and cellular longevity,
K Gundersen, and
E E Cooper, and
G Ruoff, and
T Nikolai, and
J R Assenzo
December 1973,
Acta medica Scandinavica,
K Gundersen, and
E E Cooper, and
G Ruoff, and
T Nikolai, and
J R Assenzo
May 2006,
European journal of pharmacology,
K Gundersen, and
E E Cooper, and
G Ruoff, and
T Nikolai, and
J R Assenzo
December 1998,
The American journal of clinical nutrition,
K Gundersen, and
E E Cooper, and
G Ruoff, and
T Nikolai, and
J R Assenzo
September 1979,
Canadian Medical Association journal,
K Gundersen, and
E E Cooper, and
G Ruoff, and
T Nikolai, and
J R Assenzo
December 1978,
Indian journal of experimental biology,
